Cost-effectiveness of genome-guided statin treatment for hypercholesterolemia.
MI, K., K, T., A, T., V, G., V, F., & C, M. (2026). Cost-effectiveness of genome-guided statin treatment for hypercholesterolemia.. The pharmacogenomics journal. https://doi.org/10.1038/s41397-026-00419-z
MI K, K T, A T, V G, V F, C M. Cost-effectiveness of genome-guided statin treatment for hypercholesterolemia.. The pharmacogenomics journal. 2026; doi: 10.1038/s41397-026-00419-z
MI K, K T, A T, et al. Cost-effectiveness of genome-guided statin treatment for hypercholesterolemia.[J]. The pharmacogenomics journal. 2026. DOI: 10.1038/s41397-026-00419-z.
@article{mi2026,
author = {Koufaki MI and Tzerefou K and Tyrovolas A and Gasic V and Fragoulakis V and Mitropoulou C},
title = {Cost-effectiveness of genome-guided statin treatment for hypercholesterolemia.},
journal = {The pharmacogenomics journal},
year = {2026},
doi = {10.1038/s41397-026-00419-z},
note = {PMID: 42251043},
}
TY - JOUR AU - Koufaki MI AU - Tzerefou K AU - Tyrovolas A AU - Gasic V AU - Fragoulakis V AU - Mitropoulou C TI - Cost-effectiveness of genome-guided statin treatment for hypercholesterolemia. T2 - The pharmacogenomics journal PY - 2026 DO - 10.1038/s41397-026-00419-z AN - PMID:42251043 ER -
Cardiovascular disease and hypercholesterolemia present significant global health and economic burdens. While statins are the standard treatment, individual variability and toxicities necessitate personalized approaches. This narrative review (2013-2025) evaluated the economic landscape of pharmacogenomics (PGx)-guided statin therapy and factors influencing its cost-effectiveness. Out of 219 studies, only four relevant evaluations were identified, all focusing on North American (United States & Canada) cohorts and published before 2019. Most models relied on literature-based simulations and utility data, introducing significant parameter uncertainty. Nevertheless, PGx-guided strategies generally proved cost-effective or dominant, particularly at higher willingness-to-pay thresholds, such as $50,000/QALY. In conclusion, PGx-guided therapy offers a viable pathway for improving clinical outcomes and economic efficiency. However, a paucity of raw clinical data and geographic diversity currently limit its standardized adoption. Future research must leverage real-world evidence from ongoing trials to inform robust, value-based healthcare policy.